Background: Taxanes (eg, paclitaxel) are chemotherapeutic agents that have antiproliferative, antiangiogenic, and antiinflammatory properties.
Objective: We sought to explore the safety and efficacy of paclitaxel in individuals with severe psoriasis.
Methods: An open-label, prospective, phase II pilot study was conducted at the National Institutes of Health Clinical Center, a federal government medical research facility, in Bethesda, Maryland.